Nectar Lifesciences Limited – FDA 483, Mar 10, 2023
An FDA inspection of Nectar Lifesciences Limited identified significant deficiencies in aseptic processing, environmental monitoring, and quality control systems. The firm failed to adequately conduct aseptic process simulations and airflow studies, and did not properly record interventions during manufacturing. Repeated observations highlight a lack of timely investigations into microbial data deviations and market complaints, alongside inadequate training for visual inspectors and insufficient cleaning validation for equipment.
ID · 31ca282b-7fad-44c4-8aae-a8658c493f8a
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.